Elevated CSF GPNMB levels have been suggested as a promising biomarker candidate in other neurological disorders such as amyotrophic lateral sclerosis (ALS) and neurological forms of Gaucher disease. This evidence concerns the gene GPNMB and amyotrophic lateral sclerosis.